Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1

Pediatric Blood and Cancer

Volumn 54, Issue 7, 2010, Pages 890-896

  Huttner, Anita J ^a   Kieran, Mark W ^b   Yao, Xiaopan ^b   Cruz, Lilliam ^a   Ladner, Jesse ^a   Quayle, Katherine ^a   Goumnerova, Liliana C ^a,b   Irons, Mira B ^a   Ullrich, Nicole J ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Glioblastoma; Molecular markers; Neurofibromatosis type 1; Outcome

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; INDICATOR; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TEMOZOLOMIDE; TEMSIROLIMUS; VINCRISTINE;

ARTICLE; CANCER RISK; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DATA BASE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IN SITU HYBRIDIZATION; INFANT; MALE; MEDICAL RECORD REVIEW; NEUROFIBROMATOSIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RETROSPECTIVE STUDY; SAMPLE SIZE; SURVIVAL TIME; VASCULAR NECROSIS;

BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENE DOSAGE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; NEUROFIBROMATOSIS 1; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 77951704065     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22462     Document Type: Article

References (34)

1. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1-6.
2. Yunoue S, Tokuo H, Fukunaga K, et al. Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras. J Biol Chem 2003;278:26958-26969. (Pubitemid 36876849)
3. Listernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Ann Neurol 2007;61:189-198. (Pubitemid 46557343)
4. Listernick R, Darling C, Greenwald M, et al. Optic pathway tumors in children: The effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 1995;127:718-722.
5. Distelmaier F, Fahsold R, Reifenberger G, et al. Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: The dilemma of systematic medical follow-up. Childs Nerv Syst 2007;23:343-347. (Pubitemid 46196037)
6. Uyttebroeck A, Legius E, Brock P, et al. Consecutive glioblastoma and B cell non-Hodgkin's lymphoma in a young child with von Recklinghausen's neurofibromatosis. Med Pediatr Oncol 1995;24:46-49. (Pubitemid 24373610)
7. Glover TW, Stein CK, Legius E, et al. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosomes Cancer 1991;3:62-70.
8. Hargrave DR, Zacharoulis S. Pediatric CNS tumors: Current treatment and future directions. Expert Rev Neurother 2007;7:1029-1042. (Pubitemid 47281317)
9. Arslantas A, Artan S, Oner U, et al. Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res 2007;13:39-46. (Pubitemid 46883545)
10. Houillier C, Lejeune J, Benouaich-Amiel A, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006;106:2218-2223. (Pubitemid 43673244)
11. Korshunov A, Sycheva R, Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients age <50 years. Cancer 2005;104:825-832. (Pubitemid 41113684)
12. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005;25:1-7.
13. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068.
14. Nakamura M, Shimada K, Ishida E, et al. Molecular pathogenesis of pediatric astrocytic tumors. Neuro-oncol 2007;9:113-123. (Pubitemid 46580313)
15. Biegel JA. Genetics of pediatric central nervous system tumors. J Pediatr Hematol Oncol 1997;19:492-501. (Pubitemid 28099079)
16. Rood BR, MacDonald TJ. Pediatric high-grade glioma: Molecular genetic clues for innovative therapeutic approaches. J Neuro-oncol 2005;75:267-272.
17. DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000;105:608-614. (Pubitemid 30129679)
18. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
19. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: Two challenges for the pediatric oncologist. Oncologist 2004;9:197-206. (Pubitemid 38452119)
20. Rodriguez FJ, Perry A, Gutmann DH, et al. Gliomas in neuro-fibromatosis type 1: A clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008;67:240-249. (Pubitemid 351483292)
21. Hakan T, Aker FV. Case report on a patient with neurofibromatosis type 1 and a frontal cystic glioblastoma. Neurol Neurochir Pol 2008;42:362-365.
22. Pal E, Gomori EE, Gati I. Neurofibromatosis and glioblastoma in a case of multiple sclerosis. Eur J Neurol 2001;8:717-718. (Pubitemid 35015240)
23. Unger PD, Taff ML, Song S, et al. Sudden death in a patient with Von Recklinghausen's neurofibromatosis. Am J Forensic Med Pathol 1984;5:175-179. (Pubitemid 14121568)
24. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: Prognostic significance and future therapeutic implications. Adv Anat Pathol 2003;10:212-217.
25. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-328. (Pubitemid 34266783)
26. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: Results from the Children's Cancer Group 945 cohort. J Neurosurg 2006;105:418-424.
27. Ganigi PM, Santosh V, Anandh B, et al. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: A study of 54 patients. Pediatr Neurosurg 2005;41:292-299. (Pubitemid 41636332)
28. Sung T, Miller DC, Hayes RL, et al. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000;10:249-259. (Pubitemid 30181093)
29. Cheng Y, Ng HK, Zhang SF, et al. Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 1999;30:1284-1290. (Pubitemid 29534288)
30. Kraus JA, Felsberg J, Tonn JC, et al. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neurobiol 2002;28:325-333. (Pubitemid 34989295)
31. Donson AM, Addo-Yobo SO, Handler MH, et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 2007;48:403-407.
32. Pollack IF, Hamilton RL, Sobol RW, et al. O(6)-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: Results from the CCG-945 cohort. J Clin Oncol 2006;24:3431-3437.
33. Pollack IF, Finkelstein SD, Burnham J, et al. Age and TP53 mutation frequency in childhood malignant gliomas: Results in a multi-institutional cohort. Cancer Res 2001;61:7404-7407. (Pubitemid 32995024)
34. Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005;8:119-130. (Pubitemid 41132741)